Imagene News
11 articles
The Israeli company is developing AI-based personalized medicines in collaboration with Oracle.
Imagene AI, an Israeli precision medicine company, has completed a $23 million financing round led by Oracle founder Larry Ellison, bringing its total funding to $45 million. The company specializes in AI-based personalized medicines, collaborating with Oracle and other partners. It uses data from biopsies, genomic information, and medical records to enhance clinical trials and personalize medicine. The companys technology is implemented in about 20 medical centers globally and is approved for marketing in the US, distributed by Tempus. Imagene AI collaborates with leading Israeli medical centers like Ichilov and Sheba hospitals.
InvestmentPartnersCustomers
Larry Ellison leads $23M Series B in Imagene AI to build ‘OpenAI for precision medicine’ | CTech
Imagene AI, an Israeli startup specializing in AI-driven precision medicine, has secured $23 million in a Series B funding round led by Oracle founder Larry Ellison, bringing its total funding to $45 million. The company aims to expand its offerings and enhance its activities in the pharmaceutical sector. Imagene AIs platform integrates imaging, omics, and clinical data to optimize clinical trials and personalize treatments. The company has partnered with Tempus to distribute its lung cancer detection test in the U.S. and collaborates with leading medical centers in Israel. The investment will support Imagene AIs mission to advance precision medicine and improve drug development.
InvestmentPartnersExpandCustomers
The startup has launched the CanvOI model, powered by Oracle Cloud, to advance cancer treatment.
Imagene AI, an Israeli startup, has launched the CanvOI model, an AI-powered tool for cancer diagnosis, in partnership with Oracle. The model, which operates on Oracles cloud infrastructure, was announced at Oracles annual conference in Las Vegas. Larry Ellison, Oracles founder, led a $21.5 million investment round in Imagene AI two years ago, joined by Dr. David Agus, Eyal Gura, and Blumberg Capital. The CanvOI model, described as a ChatGPT for oncology, analyzes biopsy images to provide critical data for cancer research and treatment. The launch signifies a major step forward in AI-driven cancer diagnostics.
PartnersInvestment
Imagene Advances LungOI Commercialization With New Payment Code and Pricing, Complementing Its Prior CLIA Certified US Lab
Imagene, an AI-based precision oncology pioneer, has announced key milestones in the commercialization of its AI-based NSCLC Biomarker Profiling Test, LungOI. Earlier this year, Imagene secured a novel payment code and payment rate from the Centers for Medicare and Medicaid Services (CMS). This follows the release of the LDT product to the market in Q1 2024, after receiving CLIA certification in Q1 2023. LungOI is well-positioned as a leading AI-based LDT product for detecting lung genomic alterations. Imagene is now driving the expansion of payer coverage for LungOI through early access programs.
CustomersPartners
Imagene wins the 2023 Digital Health Awards for "Best use of AI in Health Tech"
The Digital Health Hub Foundation has announced the winners of the 2023 Digital Health Hub Foundation Awards. The awards recognize the achievements of innovative health tech companies that are improving healthcare through technology. This year, over 1,500 companies applied and underwent numerous rounds of judging. The awards attracted a sold-out crowd and were sponsored by industry giants such as Genentech, Eli Lilly, Microsoft, Russell Reynolds, and Cooley. The Foundations team congratulated the winners and expressed excitement about their potential to make a lasting impact in the healthcare industry.
Customers
Imagene Announces LungOI, the First AI-Based NSCLC Molecular Panel for Immediate Cancer Biomarker Profiling
Imagene, an AI-based precision oncology company, has announced the release of LungOI, the worlds first AI-based Non-Small Cell Lung Cancer (NSCLC) molecular panel. The panel can identify actionable alterations from biopsy images within minutes, providing immediate genomic information to healthcare professionals. The technology aims to address challenges in molecular testing, such as long turnaround times and incomplete information, which can lead to suboptimal or delayed treatment. The companys executive team will be attending the upcoming World Congress of Lung Cancer in Singapore.
CustomersExpand
Imagene Launches ImageneOI Platform on Oracle Cloud Infrastructure to Democratize AI-Based Molecular Profiling in Oncology
Imagene, an AI-based precision oncology company, has launched its ImageneOI platform on Oracle Cloud Infrastructure (OCI). The platform enables rapid AI-based molecular profiling from biopsy images, overcoming limitations in current diagnostic processes. The platform has already shown significant impact in treatment initiation and averting radiation for two cancer patients. Imagene partnered with Oracle to run its ImageneOI platform on OCI, taking advantage of OCI Supercluster and OCI AI infrastructure technology. The platform aligns with oncology clinical guidelines and facilitates informed decision-making for optimal treatment strategies by reducing turnaround times from weeks to minutes.
PartnersExpand
AI Cuts Cancer Wait From Four Weeks To Two Minutes
Israeli company Imagene AI has developed an algorithm that can reduce the waiting time for cancer biopsy results from four weeks to just two minutes. The algorithm can make a near-instant diagnosis and identify the type of mutation that has caused the cancer to develop, allowing doctors to prescribe precision treatments. Imagene AIs focus is on lung and breast cancer, but the algorithm can also analyze biopsies from other organs. The AI has been implemented in hospitals under clinical trials and the company is working on receiving regulatory approval. The goal is to implement the solution in hospitals worldwide within five years.
Customers
Imagene Named 'Oncology Innovation of the Year' at 2022 BioTech Breakthrough Awards
Imagene has been selected as Oncology Innovation of the Year in the BioTech Breakthrough Awards program. The companys AI-based precision oncology technology, specifically its AI-based Biomarker Detection, was recognized for its breakthrough innovation in the field of Medical Technology. Imagenes technology allows for the real-time detection of cancerous genomic alterations from biopsy slide images using computer vision algorithms. The company has developed 28 different models for actionable alterations across eight cancer types. The technology offers fast and accurate cancer diagnosis, reducing cost and time significantly. Imagenes recognition in the awards program highlights its contribution to advancing precision oncology and improving patient care in the fight against cancer.
Customers
Imagene AI Secures $21.5 Million to Push the Boundaries of Precision Medicine for Cancer
Imagene AI, a leader in AI-based precision medicine for cancer, has raised $21.5 million in funding. The funding includes $3 million in seed funding led by Blumberg Capital and an $18.5 million Series A round led by renowned technology-driven cancer medicine investors Larry Ellison, Dr. David Agus, and Eyal Gura. Imagenes AI diagnostic technology reduces the time required for cancer biomarker detection from several weeks to just two minutes, increasing accuracy and improving treatment outcomes. The technology also enables a wider scope of treatment response-prediction and better understanding of cancer recurrence and resistance mechanisms. Imagene aims to revolutionize cancer diagnosis and transform patient care by bringing precision medicine to all cancer patients. The company collaborates with medical centers and pharmaceutical companies worldwide to accelerate the drug development process and improve therapeutic decisions for cancer patients.
Investment
Larry Ellison leads $21.5 million Series A in cancer treatment startup Imagene AI CTech
Israeli startup Imagene AI has raised $21.5 million in funding for its AI-based precision medicine technology for cancer. The funding includes $3 million in Seed funding led by Blumberg Capital and an $18.5 million Series A round led by Larry Ellison, Dr. David Agus, and Eyal Gura. Imagene AIs technology uses digitized biopsy images to deliver real-time molecular analysis, significantly reducing the time required for results. The funding will help the company further develop its diagnostic technology and expand its scope of treatment response-prediction. Imagene AI collaborates with medical centers and pharmaceutical companies worldwide.
Investment
